About Voyager Therapeutics
Voyager Therapeutics is a company based in Cambridge (United States) founded in 2014 by Steven M Paul. Voyager Therapeutics has raised $105 million across 5 funding rounds from investors including Neurocrine, Brookside Capital and Wellington. The company has 172 employees as of December 31, 2024. Voyager Therapeutics offers products and services including VY7523 and TRACER Platform. Voyager Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Spark Therapeutics, MiRagen and Poseida Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 172 as on 31 Dec, 2024
- Founders Steven M Paul
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Voyager Therapeutics, Inc.
-
Annual Revenue
$80 M (USD)-68as on Dec 31, 2024
-
Net Profit
-$65 M (USD)-149.12as on Dec 31, 2024
-
EBITDA
-$78.56 M (USD)-162.12as on Dec 31, 2024
-
Total Equity Funding
$105 M (USD)
in 5 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Jan 03, 2024
-
Investors
Neurocrine
& 5 more
-
Employee Count
172
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Voyager Therapeutics
Voyager Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VYGR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Voyager Therapeutics
Voyager Therapeutics offers a comprehensive portfolio of products and services, including VY7523 and TRACER Platform.
Therapy targeting Alzheimer's disease through genetic modification.
Platform for discovering AAV capsids to cross blood-brain barrier.
People of Voyager Therapeutics
Unlock access to complete
Unlock access to complete
Software Development Team
11 people
Leadership Team
10 people
Finance and Accounting
5 people
Senior Team
5 people
Operations Team
4 people
Product Management Team
4 people
Legal and Compliance
2 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Voyager Therapeutics
Voyager Therapeutics has successfully raised a total of $105M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Voyager Therapeutics
Voyager Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Neurocrine, Brookside Capital and Wellington.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Healthcare companies are invested in by this private equity firm.
|
Locked | Locked | Locked |
Investor details for Voyager Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Voyager Therapeutics
Investment portfolio details for Voyager Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Voyager Therapeutics
Detailed financials for Voyager Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Voyager Therapeutics Comparisons
Peer comparison for Voyager Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Voyager Therapeutics
Voyager Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Spark Therapeutics, MiRagen and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of Voyager Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Voyager Therapeutics
Complete news archive for Voyager Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Voyager Therapeutics
Voyager Therapeutics was founded in 2014.
Voyager Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Al Sandrock is the current CEO of Voyager Therapeutics.
Voyager Therapeutics is a funded company, having raised a total of $105M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Voyager Therapeutics is 172.
Annual revenue of Voyager Therapeutics is $80M as on Dec 31, 2024.
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The companys initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinsons disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreichs ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Voyager Therapeutics's top competitors include Spark Therapeutics, Entrada Therapeutics and Annexon.
Voyager Therapeutics offers VY7523 and TRACER Platform.
Yes, Voyager Therapeutics is publicly traded on NASDAQ under the ticker symbol VYGR.
Voyager Therapeutics has 6 investors. Key investors include Neurocrine, Brookside Capital, Wellington, Casdin Capital, and PFM Health Sciences.
The ticker symbol of Voyager Therapeutics is VYGR on NASDAQ.